ZHZheng

Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Fengqin Xiong

    State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    1 shared publication
  • Hao Wang

    China State Institute of Pharmaceutical Industry, Shanghai 201203, China

    1 shared publication
  • Helen He Zhu

    State Key Laboratory of Systems Medicine for Cancer, Department of Urology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China

    1 shared publication
  • Lingli Zhou

    State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    1 shared publication
  • Linyang Jiang

    State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    1 shared publication
  • Pengcheng Zhang

    School of Biomedical Engineering, ShanghaiTech University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles

    by Chao Zheng, Wen Zhang, Xiang Gong, Fengqin Xiong, Linyang Jiang, Lingli Zhou, Yuan Zhang, Helen He Zhu, Hao Wang, Yaping Li, et al.

    Immunotoxicity remains a major hindrance to chemotherapy in cancer therapy. Nanocarriers may alleviate the immunotoxicity, but the optimal design remains unclear. Here, we created two variants of maytansine (DM1)–loaded synthetic high-density lipoproteins (D-sHDL) with either physically entrapped ( E D-sHDL) or chemically conjugated ( C D-sHDL) DM1. We found that C D-sHDL showed less accumulation in the tumor draining lymph nodes (DLNs) and femur, resulting in a lower toxicity against myeloid cells than E D-sHDL via avoiding scavenger receptor class B type 1 (SR-B1)–mediated DM1 transportation into the granulocyte-monocyte progenitors and dendritic cells. Therefore, higher densities of lymphocytes in the tumors, DLNs, and blood were recorded in mice receiving C D-sHDL, leading to a better efficacy and immune memory of C D-sHDL against colon cancer. Furthermore, liposomes with conjugated DM1 ( C D-Lipo) showed lower immunotoxicity than those with entrapped drug ( E D-Lipo) through the same mechanism after apolipoprotein opsonization. Our findings highlight the critical role of drug loading patterns in dictating the biological fate and activity of nanomedicine.